Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
This cell will serve as an extension of the Tele Mental Health Assistance and Networking Across States initiative of the Ministry of Health and Family welfare
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Subscribe To Our Newsletter & Stay Updated
